Investment Analysts’ Weekly Ratings Updates for Dyne Therapeutics (DYN)

A number of firms have modified their ratings and price targets on shares of Dyne Therapeutics (NASDAQ: DYN) recently:

• 9/30/2026 – Dyne Therapeutics was given a new $37.00 price target by Stifel Nicolaus.
• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Cantor Fitzgerald.
• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $50.00 price target on the stock.
• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
• 9/30/2026 – Dyne Therapeutics had its price target lowered by HC Wainwright from $50.00 to $32.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Dyne Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $47.00 price target on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Morgan Stanley from $45.00 to $36.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Robert W. Baird from $30.00 to $26.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Royal Bank Of Canada from $35.00 to $30.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics was downgraded by JPMorgan Chase & Co. from “neutral” to “underweight”. They now have a $10.00 price target on the stock, down from $17.00.
• 9/8/2026 – Dyne Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $37.00 price target on the stock.
• 8/17/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Insider Activity

In related news, Director Jason Rhodes sold 2,160,516 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 2,598,706 shares of company stock worth $65,432,671. 9.46% of the stock is owned by insiders.

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.